IL181575D0 - Anti-ox40l antibodies - Google Patents

Anti-ox40l antibodies

Info

Publication number
IL181575D0
IL181575D0 IL18157507A IL18157507A IL181575D0 IL 181575 D0 IL181575 D0 IL 181575D0 IL 18157507 A IL18157507 A IL 18157507A IL 18157507 A IL18157507 A IL 18157507A IL 181575 D0 IL181575 D0 IL 181575D0
Authority
IL
Israel
Prior art keywords
anti
ox40l antibodies
ox40l
antibodies
Prior art date
Application number
IL18157507A
Other versions
IL181575A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP04022158 priority Critical
Priority to EP04030546 priority
Priority to PCT/EP2005/009968 priority patent/WO2006029879A2/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL181575D0 publication Critical patent/IL181575D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL181575(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IL181575A publication Critical patent/IL181575A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
IL18157507A 2004-09-17 2007-02-26 Human and humanized antibodies binding to ox40l, method for their preparation and uses thereof in the manufacture of medicaments for the prophylaxis and treatment of inflammatory disorders IL181575A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04022158 2004-09-17
EP04030546 2004-12-23
PCT/EP2005/009968 WO2006029879A2 (en) 2004-09-17 2005-09-16 Anti-ox40l antibodies

Publications (2)

Publication Number Publication Date
IL181575D0 true IL181575D0 (en) 2007-07-04
IL181575A IL181575A (en) 2012-07-31

Family

ID=35462606

Family Applications (1)

Application Number Title Priority Date Filing Date
IL18157507A IL181575A (en) 2004-09-17 2007-02-26 Human and humanized antibodies binding to ox40l, method for their preparation and uses thereof in the manufacture of medicaments for the prophylaxis and treatment of inflammatory disorders

Country Status (20)

Country Link
US (3) US7501496B1 (en)
EP (2) EP1791869B1 (en)
JP (2) JP4594986B2 (en)
KR (2) KR100901090B1 (en)
CN (1) CN101684157A (en)
AR (1) AR051925A1 (en)
AU (1) AU2005284310B2 (en)
BR (1) BRPI0515554A (en)
CA (1) CA2580140C (en)
CL (1) CL2010000426A1 (en)
ES (1) ES2433916T3 (en)
HK (1) HK1108000A1 (en)
IL (1) IL181575A (en)
MX (1) MX2007002905A (en)
MY (1) MY149442A (en)
NZ (2) NZ579022A (en)
RU (2) RU2423383C2 (en)
SG (1) SG147444A1 (en)
TW (2) TWI380996B (en)
WO (1) WO2006029879A2 (en)

Families Citing this family (416)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
ES2654040T3 (en) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for the purification of bispecific antibodies
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
WO2008127271A2 (en) * 2006-09-08 2008-10-23 Abbott Laboratories Interleukin -13 binding proteins
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR101575914B1 (en) 2007-09-26 2015-12-08 추가이 세이야쿠 가부시키가이샤 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
RS53174B (en) 2007-10-05 2014-06-30 Genentech Inc. Use of anti-amyloid beta antibody in ocular diseases
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
CA2751477C (en) 2009-02-17 2019-08-27 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
AR075925A1 (en) 2009-03-25 2011-05-04 Genentech Inc Anti-alfa5beta1 (alfa5beta1: integrin glycoprotein) and their uses
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
HUE025190T2 (en) 2009-12-22 2016-02-29 F Hoffmann-La Roche Ag Sequence dependent aggregation
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
AU2011232514A1 (en) 2010-03-24 2012-08-30 Genentech, Inc. Anti-LRP6 antibodies
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2582729A4 (en) 2010-06-18 2014-05-28 Hoffmann La Roche Anti-axl antibodies and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
BR112013000340A2 (en) 2010-07-09 2016-05-31 Genentech Inc isolated antibody that binds neuropillin-1 (nrp1), isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate and method of detecting nrp1 in a biological sample
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP6081356B2 (en) 2010-07-30 2017-02-15 エーシー イミューン エス.エー. Safe and functional humanized anti-β-amyloid antibody
JP2013541937A (en) 2010-08-05 2013-11-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Anti-MHC antibody-antiviral cytokine fusion protein
MX358859B (en) 2010-08-13 2018-09-05 Roche Glycart Ag ANTI-FAP ANTIBODIES and METHODS OF USE.
MX2013001336A (en) 2010-08-13 2013-03-08 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use.
AU2012299421B2 (en) * 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
SI2609118T1 (en) 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
CA2815840A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
RU2013139267A (en) 2011-02-10 2015-03-20 Рош Гликарт Аг Improved immunotherapy
KR102003075B1 (en) * 2011-02-23 2019-07-23 에프. 호프만-라 로슈 아게 Antibodies against human il33r and uses thereof
NZ614658A (en) 2011-03-29 2015-07-31 Roche Glycart Ag Antibody fc variants
EP2694551A1 (en) 2011-04-07 2014-02-12 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг Immunoconjugates containing interleukin-2 mutant polypetips
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
CA2834879C (en) 2011-05-16 2019-10-22 Genentech, Inc. Fgfr1 agonists and methods of use
CN108892726A (en) * 2011-06-13 2018-11-27 艾比吉诺米克斯合作公司 Anti- PSGL-1 antibody and application thereof
CA2837914A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
CN110229235A (en) 2011-06-22 2019-09-13 霍夫曼-拉罗奇有限公司 Target cell is removed by the HIV-specific cytotoxic T lymphocytes in circulation using the compound comprising MHC I class
JP2014522843A (en) 2011-06-30 2014-09-08 ジェネンテック, インコーポレイテッド Anti-C-MET antibody preparation
KR20140057326A (en) 2011-08-17 2014-05-12 제넨테크, 인크. Neuregulin antibodies and uses thereof
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20130058937A1 (en) 2011-08-23 2013-03-07 Johannes Auer Bispecific antigen binding molecules
US9309306B2 (en) 2011-08-23 2016-04-12 Roche Glycart Ag Anti-MCSP antibodies
JP6339015B2 (en) 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
JP2014533927A (en) 2011-09-15 2014-12-18 ジェネンテック, インコーポレイテッド How to promote differentiation
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
TR201811270T4 (en) 2011-10-14 2018-08-27 Hoffmann La Roche Anti-htra1 antibodies and methods of use.
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
MX2014004991A (en) 2011-10-28 2014-05-22 Genentech Inc Therapeutic combinations and methods of treating melanoma.
US9040048B2 (en) 2011-11-11 2015-05-26 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
AU2012340826A1 (en) 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
AR089434A1 (en) 2011-12-23 2014-08-20 Genentech Inc Process for preparing formulations with high protein concentration
CN104411717A (en) 2012-01-09 2015-03-11 斯克利普斯研究所 Humanized antibodies with ultralong CDR3S
CN104520321A (en) 2012-01-09 2015-04-15 斯克利普斯研究所 Ultralong complementarity determining regions and uses thereof
TW201335187A (en) 2012-01-18 2013-09-01 Genentech Inc Anti-LRP5 antibodies and methods of use
CN104168920A (en) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of using FGF19 modulators
CN104718220A (en) 2012-02-11 2015-06-17 霍夫曼-拉罗奇有限公司 R-spondin translocations and methods using the same
JP6152120B2 (en) 2012-02-15 2017-06-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Affinity chromatography based on Fc receptors
MX2014011500A (en) 2012-03-27 2014-12-05 Genentech Inc Diagnosis and treatments relating to her3 inhibitors.
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc Antibodies and immunoconjugates LGR5
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
KR101843614B1 (en) 2012-05-23 2018-03-29 제넨테크, 인크. Selection method for therapeutic agents
CN104364266A (en) 2012-06-15 2015-02-18 霍夫曼-拉罗奇有限公司 Anti-PCSK9 antibodies, formulations, dosing, and methods of use
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
CN104394886B (en) 2012-07-04 2017-05-24 弗·哈夫曼-拉罗切有限公司 Anti-theophylline antibodies and methods of use
EP2870180A1 (en) 2012-07-04 2015-05-13 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
RU2684595C2 (en) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Kovalent-related conjuates of antigen-antibody
MX356162B (en) 2012-07-05 2018-05-16 Genentech Inc Expression and secretion system.
WO2014011519A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
TW201408697A (en) 2012-07-09 2014-03-01 Genentech Inc Anti-CD79b antibodies and immunoconjugates
WO2014011518A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
TW201408696A (en) 2012-07-09 2014-03-01 Genentech Inc Anti-CD22 antibodies and immunoconjugates
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
RU2650788C2 (en) 2012-08-07 2018-04-17 Роше Гликарт Аг Composition comprising two antibodies engineered to have reduced and increased effector function
MX2015001675A (en) 2012-08-08 2015-04-10 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof.
KR20150041626A (en) 2012-08-09 2015-04-16 로슈 글리카트 아게 Asgpr antibodies and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP6479660B2 (en) 2012-08-24 2019-03-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antibodies and vaccines for use in treating ROR1 cancer and inhibiting metastasis
EP2917243B1 (en) 2012-11-08 2018-03-14 F.Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
JP6475167B2 (en) 2012-12-21 2019-02-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Multifunctional protein containing disulfide-linked multivalent MHC class I
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
CN104994879A (en) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
CN104936987A (en) 2013-02-26 2015-09-23 罗切格利卡特公司 Anti-MCSP antibodies
MA38308A1 (en) 2013-02-26 2018-02-28 Hoffmann La Roche binding molecules to the antigen bispecific activating T lymphocytes
JP6499087B2 (en) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
CN104936985A (en) 2013-02-26 2015-09-23 罗切格利卡特公司 Bispecific T cell activating antigen binding molecules
EP2964260A2 (en) 2013-03-06 2016-01-13 F.Hoffmann-La Roche Ag Methods of treating and preventing cancer drug resistance
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2016515132A (en) 2013-03-14 2016-05-26 ジェネンテック, インコーポレイテッド Combination and use of MEK inhibitor compounds with HER3 / EGFR inhibitor compounds
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
KR20150131177A (en) 2013-03-15 2015-11-24 제넨테크, 인크. Anti-crth2 antibodies and their use
AU2014235453A1 (en) 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
KR20150128707A (en) 2013-03-15 2015-11-18 제넨테크, 인크. Compositions and methods for diagnosis and treatment of hepatic cancers
KR20150131163A (en) 2013-03-15 2015-11-24 에이씨 이뮨 에스.에이. Anti-tau antibodies and methods of use
PT2970422T (en) 2013-03-15 2018-07-06 Hoffmann La Roche Il-22 polypeptides and il-22 fc fusion proteins and methods of use
SG11201507781VA (en) * 2013-03-18 2015-10-29 Biocerox Products B V Humanized anti-cd134 (ox40) antibodies and uses thereof
TR201905458T4 (en) 2013-04-03 2019-05-21 Roche Glycart Ag FAP and bispecific antibodies specific for DR5-specific antibodies and methods of use thereof for DR5.
PL2992012T3 (en) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
EP3594240A1 (en) 2013-05-20 2020-01-15 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
RU2016109247A (en) 2013-09-17 2017-10-19 Дженентек, Инк. Ways of application of antibodies to lgr5
BR112016007635A2 (en) 2013-10-11 2017-09-12 Genentech Inc nsp4 inhibitors and methods of use
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
KR20160070136A (en) 2013-10-18 2016-06-17 제넨테크, 인크. Anti-rsp02 and/or anti-rsp03 antibodies and their uses
WO2015061441A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
BR112016010065A2 (en) 2013-11-21 2017-12-05 Hoffmann La Roche alpha-synuclein antibodies and methods of use
AU2014362238A1 (en) 2013-12-13 2016-06-09 Genentech, Inc. Anti-CD33 antibodies and immunoconjugates
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
CA2933883A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP6608827B2 (en) 2013-12-20 2019-11-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Humanized anti-tau (pS422) antibodies and methods of use
AU2014369982B2 (en) 2013-12-24 2019-04-18 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2015101589A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
CN105873615A (en) 2014-01-03 2016-08-17 豪夫迈·罗氏有限公司 Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
JP6557664B2 (en) 2014-01-06 2019-08-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Monovalent blood-brain barrier shuttle module
EP3094647A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
RU2016130349A3 (en) 2014-01-24 2018-09-24
CN105980410A (en) 2014-02-06 2016-09-28 豪夫迈·罗氏有限公司 Interleukin-2 fusion proteins and uses thereof
RU2016132162A3 (en) 2014-02-08 2018-11-20
SG11201606316XA (en) 2014-02-08 2016-08-30 Genentech Inc Methods of treating alzheimer's disease
CA2936565A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
CN108064169A (en) 2015-03-03 2018-05-22 科马布有限公司 Antibody, purposes and method
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
AU2015241037A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Anti-OX40 antibodies and methods of use
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
RU2016150370A (en) 2014-05-22 2018-06-26 Дженентек, Инк. Antibodies and immunoconjugates against GPC3
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2016016233A (en) 2014-06-11 2017-03-31 Genentech Inc Anti-lgr5 antibodies and uses thereof.
AP201709674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
AR100978A1 (en) 2014-06-26 2016-11-16 F Hoffmann-La Roche Ag SHUTTLE BRAIN OF ANTI-Tau Humanized Antibody (pS422) AND USES THEREOF
JP2017165652A (en) * 2014-06-30 2017-09-21 国立大学法人東北大学 Novel anti-human ox40 ligand antibody, and anti-influenza agent comprising the same
US9914774B2 (en) 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition
AU2015288232A1 (en) 2014-07-11 2017-03-02 Genentech, Inc. Anti-PD-L1 antibodies and diagnostic uses thereof
CA2957314A1 (en) * 2014-08-04 2016-02-11 Baylor Research Institute Antagonistic anti-ox40l antibodies and methods of their use
JP2017534256A (en) 2014-09-12 2017-11-24 ジェネンテック, インコーポレイテッド ANTI-CLL-1 antibody and immune complex
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN107124870A (en) 2014-09-17 2017-09-01 基因泰克公司 Immunoconjugates comprising Anti-HER 2 and Pyrrolobenzodiazepines *
EP3207057A2 (en) 2014-10-16 2017-08-23 F.Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
AR102537A1 (en) 2014-11-05 2017-03-08 Flexus Biosciences Inc immunomodulatory agents
AU2015342964A1 (en) 2014-11-05 2017-06-15 Genentech, Inc. Methods of producing two chain proteins in bacteria
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc Modulatory compounds indoleamine 2,3 dioxygenase enzyme (left), and methods of synthesising pharmaceutical compositions containing them
CN108064308A (en) 2014-11-05 2018-05-22 豪夫迈·罗氏有限公司 The method that dichain proteins are generated in bacterium
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
CN107105632A (en) 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 Nephrosis animal model and its therapeutic agent
JP2018500883A (en) 2014-11-10 2018-01-18 ジェネンテック, インコーポレイテッド Anti-interleukin-33 antibody and use thereof
AU2015345024A1 (en) 2014-11-14 2017-04-20 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a TNF family ligand trimer
JP2017537090A (en) 2014-11-17 2017-12-14 ジェネンテック, インコーポレイテッド Combination therapy comprising OX40 binding agonist and PD-1 axis binding antagonist
CN107108745A (en) 2014-11-19 2017-08-29 基因泰克公司 Anti- BACE1 antibody is used for the purposes of neural disease immunotherapy with it
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
CN107250158A (en) 2014-11-19 2017-10-13 基因泰克公司 Anti-rotation Human Placental Ferritin Receptor/anti-BACE1 multi-specificity antibodies and application method
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
PE20170953A1 (en) 2014-12-05 2017-07-13 Genentech Inc CD79b antibodies and methods of use
EP3230317A2 (en) 2014-12-10 2017-10-18 Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
AR103232A1 (en) 2014-12-22 2017-04-26 Bristol-Myers Squibb Company ANTAGONISTS TGFbR
JP2018511557A (en) 2015-01-22 2018-04-26 中外製薬株式会社 Combination and use of two or more anti-C5 antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US20180246113A1 (en) 2015-02-05 2018-08-30 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
TN2017000374A1 (en) 2015-03-02 2019-01-16 Squibb Bristol Myers Co TGF-β INHIBITORS
EP3271723A1 (en) 2015-03-16 2018-01-24 H. Hoffnabb-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN107743490A (en) 2015-04-03 2018-02-27 百时美施贵宝公司 For the indoleamine 2 for the treatment of cancer, 3 dioxygenase inhibitors
EP3277314A4 (en) 2015-04-03 2018-08-29 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
KR20180002653A (en) 2015-04-07 2018-01-08 제넨테크, 인크. Antigen binding complexes having an agonistic activity activity and methods of use
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
EP3283527A1 (en) 2015-04-13 2018-02-21 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN107969128A (en) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 Immune modulator with adjustable affinity
JP2018516549A (en) 2015-04-24 2018-06-28 ジェネンテック, インコーポレイテッド Methods for identifying bacteria containing binding polypeptides
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
MX2017014188A (en) 2015-05-07 2018-04-10 Agenus Inc Anti-ox40 antibodies and methods of use thereof.
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2984003A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2018520658A (en) 2015-05-29 2018-08-02 ジェネンテック, インコーポレイテッド Humanized anti-Ebola virus glycoprotein antibodies and uses thereof
CN107810012A (en) 2015-06-02 2018-03-16 豪夫迈·罗氏有限公司 Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34
CA2986942A1 (en) 2015-06-05 2016-12-08 Genentech, Inc. Anti-tau antibodies and methods of use
MX2017015937A (en) 2015-06-08 2018-12-11 Genentech Inc Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
CN108064246A (en) 2015-06-15 2018-05-22 基因泰克公司 Antibody and immune conjugate
JP2018522541A (en) 2015-06-16 2018-08-16 ジェネンテック, インコーポレイテッド Anti-CLL-1 antibody and method of use
JP2018527887A (en) 2015-06-16 2018-09-27 ジェネンテック, インコーポレイテッド Humanized affinity matured antibodies against FcRH5 and methods of use
CN107849145A (en) 2015-06-16 2018-03-27 基因泰克公司 Anti-cd 3 antibodies and its application method
AU2016280070A1 (en) 2015-06-17 2017-12-07 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
CN107787331A (en) 2015-06-17 2018-03-09 豪夫迈·罗氏有限公司 Anti-HER 2 and application method
EP3313885A1 (en) 2015-06-29 2018-05-02 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody for use in organ transplantation
CN107922500A (en) 2015-06-29 2018-04-17 洛克菲勒大学 The anti-CD 40 antibodies of agonist activity with enhancing
EP3313878A1 (en) 2015-06-29 2018-05-02 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
JP2018526344A (en) 2015-07-28 2018-09-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company TGF beta receptor antagonist
JP2018525415A (en) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company TGF beta receptor antagonist
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
JP6266164B2 (en) 2015-09-18 2018-01-31 中外製薬株式会社 Antibodies that bind to IL-8 and uses thereof
JP2018535649A (en) 2015-09-22 2018-12-06 スプリング バイオサイエンス コーポレーション Anti-OX40 antibody and diagnostic use thereof
KR20180053315A (en) 2015-09-23 2018-05-21 제넨테크, 인크. Optimized variants of anti-VEGF antibodies
RU2018115246A (en) 2015-09-24 2019-10-28 АБВИТРО ЭлЭлСи Compositions of antibodies to hiv and ways of their application
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
EP3356417A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
US20170096495A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2017055314A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CN107849137A (en) 2015-10-02 2018-03-27 豪夫迈·罗氏有限公司 The anti-CEAXCD3 T cell activations antigen binding molecules of bispecific
CN108137697A (en) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 Bispecific anti-humen CD 20/human TfR antibody and application method
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP2018535662A (en) 2015-10-02 2018-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody to costimulatory TNF receptor
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
AR106189A1 (en) 2015-10-02 2017-12-20 F Hoffmann-La Roche Ag Bispecific antibodies against human Ab AND human transferrin receptor and methods of use
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017059289A1 (en) 2015-10-02 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
CN108136045A (en) 2015-10-20 2018-06-08 基因泰克公司 Calicheamicin-antibody-drug conjugate and application method
JP2018535670A (en) 2015-10-29 2018-12-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Anti-variant Fc region antibodies and methods of use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
BR112018008865A8 (en) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polypeptides of the extracellular domain of CD80 and its use in cancer treatment
CN108602884A (en) 2015-11-08 2018-09-28 豪夫迈·罗氏有限公司 The method for screening multi-specificity antibody
KR20180082563A (en) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 Antibodies to glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3377533A2 (en) 2015-11-19 2018-09-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017091580A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN108602829A (en) 2015-12-15 2018-09-28 百时美施贵宝公司 Cxcr4 receptor antagonists
BR112018014762A2 (en) 2016-01-20 2018-12-26 Genentech Inc method of treating (early) alzheimer's disease
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
JP2019513695A (en) 2016-02-29 2019-05-30 ジェネンテック, インコーポレイテッド Therapeutic method and diagnostic method for cancer
SG11201806861SA (en) 2016-03-04 2018-09-27 Squibb Bristol Myers Co Combination therapy with anti-cd73 antibodies
AU2017235097A1 (en) 2016-03-15 2018-09-20 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
EP3433280A1 (en) 2016-03-22 2019-01-30 H. Hoffnabb-La Roche Ag Protease-activated t cell bispecific molecules
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
CN109154027A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
CN109154613A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
AU2017250358A1 (en) 2016-04-15 2018-10-18 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
EP3443000A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CN109071652A (en) 2016-05-11 2018-12-21 豪夫迈·罗氏有限公司 Antigen binding molecules comprising TNF family ligand trimer and tenascin binding modules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN109152843A (en) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 PROTAC antibody conjugates and its application method
JP2019519769A (en) 2016-05-27 2019-07-11 ジェネンテック, インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug complexes
WO2018220099A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
JP2019527673A (en) 2016-06-06 2019-10-03 ジェネンテック, インコーポレイテッド Sylvestrol antibody-drug conjugate and method of use
US20190177404A1 (en) 2016-06-15 2019-06-13 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
EP3475298A1 (en) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
EP3478717A1 (en) 2016-07-04 2019-05-08 H. Hoffnabb-La Roche Ag Novel antibody format
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3492496A1 (en) 2016-07-29 2019-06-05 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
JP2019530434A (en) 2016-08-05 2019-10-24 ジェネンテック, インコーポレイテッド Multivalent and multi-epitope antibodies with agonist activity and methods of use
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3347379B1 (en) 2016-08-17 2019-11-06 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3515932A1 (en) 2016-09-19 2019-07-31 H. Hoffnabb-La Roche Ag Complement factor based affinity chromatography
JP2019533646A (en) 2016-09-23 2019-11-21 ジェネンテック, インコーポレイテッド Use of IL-13 antagonists to treat atopic dermatitis
CN109843926A (en) 2016-09-30 2019-06-04 豪夫迈·罗氏有限公司 For the bispecific antibody of CD3
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
AU2017339517A1 (en) 2016-10-06 2019-04-18 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3526254A1 (en) 2016-10-12 2019-08-21 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
EP3529350A1 (en) 2016-10-19 2019-08-28 H. Hoffnabb-La Roche Ag Method for producing an immunoconjugate
CN110121509A (en) 2016-10-26 2019-08-13 西达-赛奈医疗中心 Neutralize anti-TL1A monoclonal antibody
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017361081A1 (en) 2016-11-15 2019-05-23 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
BR112019010128A2 (en) 2016-11-19 2019-10-08 Potenza Therapeutics Inc anti-gitr antigen binding proteins and methods of use thereof
CN110023334A (en) 2016-11-21 2019-07-16 科雅博有限责任公司 Anti- GP73 antibody and immune conjugate
CN110248959A (en) 2016-12-07 2019-09-17 基因泰克公司 Anti- TAU antibody and application method
EP3551220A1 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of use
TW201827076A (en) 2016-12-12 2018-08-01 美商建南德克公司 Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
TW201825520A (en) 2016-12-15 2018-07-16 美商艾伯維生物醫療股份有限公司 Anti-ox40 antibodies and their uses
KR20190097039A (en) 2016-12-19 2019-08-20 에프. 호프만-라 로슈 아게 Combination Therapy with Targeted 4-1BB (CD137) Agonists
CN110088135A (en) 2016-12-20 2019-08-02 豪夫迈·罗氏有限公司 The combination treatment of anti-CD20/ AntiCD3 McAb bispecific antibody and 4-1BB (CD137) agonist
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
KR20190082942A (en) 2016-12-21 2019-07-10 에프. 호프만-라 로슈 아게 In-vitro manipulation of antibodies
WO2018114878A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
BR112019012796A2 (en) 2016-12-23 2019-12-03 Potenza Therapeutics Inc antineuropillin antigen binding proteins and methods of use thereof
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CR20190403A (en) 2017-01-31 2019-10-10 Hoffmann La Roche A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AR110873A1 (en) 2017-02-10 2019-05-08 Genentech Inc Antibodies against tryptase, these compositions and uses of these
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
TW201837467A (en) 2017-03-01 2018-10-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
AU2018232698A1 (en) 2017-03-10 2019-08-15 F. Hoffmann-La Roche Ag Method for producing multispecific antibodies
EP3596116A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
CN110662758A (en) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 CD80 variant immunomodulatory proteins and uses thereof
AU2018237359A1 (en) 2017-03-22 2019-10-10 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
AU2018241624A1 (en) 2017-03-27 2019-10-03 F. Hoffmann-La Roche Ag Improved antigen binding receptors
WO2018183175A1 (en) 2017-03-28 2018-10-04 Genentech, Inc. Methods of treating neurodegenerative diseases
SG11201908092RA (en) 2017-03-30 2019-10-30 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
WO2018184964A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
KR20190136054A (en) 2017-04-03 2019-12-09 에프. 호프만-라 로슈 아게 Antibody That Binds STEAP-1
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3053360A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Anti-lag3 antibodies
TW201843173A (en) 2017-04-07 2018-12-16 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN110505883A (en) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 Proleulzin immunoconjugates used in method for treating cancer, CD40 agonist, and optionally PD-1 axis binding antagonists
CN110621787A (en) 2017-04-14 2019-12-27 豪夫迈·罗氏有限公司 Methods for diagnosis and treatment of cancer
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
TW201902915A (en) 2017-04-27 2019-01-16 美商提薩羅有限公司 For lymphocyte activation gene -3 (lag-3) of an antibody and uses thereof agent
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20180344869A1 (en) 2017-05-18 2018-12-06 Hoffmann-La Roche Inc. Reduction of application-related side reaction of a therapeutic antibody
AU2018271915A1 (en) * 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
WO2018217944A1 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2019018757A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US20190119396A1 (en) 2017-07-26 2019-04-25 Forty Seven, Inc. Anti-SIRP-Alpha Antibodies and Related Methods
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US20190083641A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
TW201925223A (en) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 Variant ICOS ligand immunomodulatory proteins and related compositions and methods
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies
WO2019086362A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
WO2019086497A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
WO2019086499A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Novel tnf family ligand trimer-containing antigen binding molecules
WO2019086500A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
WO2019086395A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Trifab-contorsbody
TW201923089A (en) 2017-11-06 2019-06-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
TW201930356A (en) 2017-12-21 2019-08-01 瑞士商赫孚孟拉羅股份公司 Antibodies binding to HLA-A2/WT1
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019134981A1 (en) 2018-01-05 2019-07-11 Ac Immune Sa Misfolded tdp-43 binding molecules
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
TW201938186A (en) 2018-01-26 2019-10-01 美商建南德克公司 IL-22 FC fusion proteins and methods of use
WO2019148020A1 (en) 2018-01-26 2019-08-01 Genentech, Inc. Compositions and methods of use
US20190270814A1 (en) 2018-02-08 2019-09-05 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TW201936641A (en) 2018-02-09 2019-09-16 瑞士商赫孚孟拉羅股份公司 Antibodies binding to GPRC5D
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019158645A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2019173587A1 (en) 2018-03-08 2019-09-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019175125A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
WO2019178316A1 (en) 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
WO2019190969A1 (en) 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
WO2019195514A1 (en) 2018-04-04 2019-10-10 Genentech, Inc. Methods for detecting and quantifying fgf21
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2019200256A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
WO2019197600A1 (en) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
US20190314390A1 (en) 2018-04-16 2019-10-17 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019202041A1 (en) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Multispecific antibodies and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
WO2019231243A1 (en) * 2018-05-29 2019-12-05 사회복지법인 삼성생명공익재단 Feeder cell expressing ox40l and method for culturing natural killer cells using same
WO2019233842A1 (en) 2018-06-08 2019-12-12 F. Hoffmann-La Roche Ag Peptidic linker with reduced post-translational modification
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20190389906A1 (en) 2018-06-22 2019-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006018A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
WO2020006016A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2020014132A2 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
WO2020014327A2 (en) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
AT118784T (en) 1985-07-12 1995-03-15 Univ New York With the plasmodium vivax circumsporozoite protein matching immunogenic peptide antigen.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5112516A (en) 1991-01-11 1992-05-12 William D. Sheldon, III High temperature flashpoint, stable cleaning composition
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapy Use of the chimeric antibody and radiolabeled antibodies to human b-lymphocyte-restricted differentiation antigen for treatment of B-cell lymphoma
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (en) 1997-09-25 2007-05-16 武田薬品工業株式会社 Pharmaceutical composition containing gp34 binding inhibitor as active ingredient
ES2230848T3 (en) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity.
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA02001911A (en) 1999-08-24 2003-07-21 Medarex Inc Human ctla 4 antibodies and their uses.
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
WO2001094586A2 (en) 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
US20040009174A1 (en) * 2001-12-18 2004-01-15 Arndt Gregory Martin Method of treating asthma
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties

Also Published As

Publication number Publication date
EP2218782A2 (en) 2010-08-18
EP2218782A3 (en) 2011-01-26
US20100166740A1 (en) 2010-07-01
AU2005284310B2 (en) 2012-01-19
JP2008512995A (en) 2008-05-01
CA2580140C (en) 2016-03-15
KR20070050972A (en) 2007-05-16
RU2007114328A (en) 2008-10-27
NZ579022A (en) 2010-04-30
TW200911838A (en) 2009-03-16
SG147444A1 (en) 2008-11-28
WO2006029879A2 (en) 2006-03-23
EP1791869A2 (en) 2007-06-06
RU2009126723A (en) 2011-01-20
HK1108000A1 (en) 2013-10-18
US20110070239A1 (en) 2011-03-24
AR051925A1 (en) 2007-02-21
KR100901090B1 (en) 2009-06-08
CL2010000426A1 (en) 2010-10-01
RU2395523C2 (en) 2010-07-27
KR100895597B1 (en) 2009-05-06
WO2006029879A3 (en) 2006-09-08
MX2007002905A (en) 2007-05-08
EP1791869B1 (en) 2013-07-31
CA2580140A1 (en) 2006-03-23
US9102733B2 (en) 2015-08-11
BRPI0515554A (en) 2008-07-29
CN101684157A (en) 2010-03-31
ES2433916T3 (en) 2013-12-13
KR20080059471A (en) 2008-06-27
TW200621805A (en) 2006-07-01
JP4594986B2 (en) 2010-12-08
NZ553333A (en) 2009-09-25
RU2423383C2 (en) 2011-07-10
TWI380996B (en) 2013-01-01
US7868141B2 (en) 2011-01-11
US7501496B1 (en) 2009-03-10
TWI309240B (en) 2009-05-01
MY149442A (en) 2013-08-30
AU2005284310A1 (en) 2006-03-23
JP2010280673A (en) 2010-12-16
IL181575A (en) 2012-07-31

Similar Documents

Publication Publication Date Title
TWI346544B (en) Knochenschraube
TWI455946B (en) Anti-glypican 3 antibody
IL211393A (en) Antibody formulations
ZA200609595B (en) Novel CIS-Imidazolines
GB0426736D0 (en) MyFone
SI1802198T1 (en) Synergistische fungizide Zusammensetzungen
DE602005003960D1 (en) Oximesther-fotoinitiatoren
DE602005017576D1 (en) Wirbel-osteosynthese-gerät
DE602005025924D1 (en) Royl-coa-desaturase
EP1769743A4 (en) Radiotomograph
DE602005022165D1 (en) Fluidleitungsverbindervorrichtung
DE602005003667D1 (en) Sandwich-hybridmontagematte
DE602005025220D1 (en) Thernet-kabel
DE602005020252D1 (en) Röhrenförmige prothese
IL175710D0 (en) Anti-mpl antibody
ZA200608234B (en) Anti-P-selectin antibodies
GB0312481D0 (en) Antibodies
IL179672D0 (en) Anti-cd3 antibodies
IL187106A (en) Sclerostin-binding antibody
IL179730D0 (en) Novel cis-imidazolines
IL190472D0 (en) Anti-glypican-3 antibody
DE502005007844D1 (en) Phasenstabile polyurethanprepolymere
IL177956A (en) Anti-myostatin antibodies
TWI346750B (en) Planetenradgetriebe
IL215027D0 (en) ANTI-zB7R1 ANTIBODY

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees